(Q37926915)

English

Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis

scientific article published on 06 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 August 2017

0 references

1 reference

Europe PubMed Central

Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

25 August 2017

0 references

systematic review

1 reference

based on heuristic

inferred from title

ulcerative colitis

1 reference

based on heuristic

inferred from title

Alexander C. Ford

1

1 reference

Europe PubMed Central

25 August 2017

object named as

Paul Moayyedi

5

0 references

William Jeffery Sandborn

3

object named as

William J Sandborn

1 reference

Europe PubMed Central

25 August 2017

author name string

Khurram J Khan

2

1 reference

Europe PubMed Central

25 August 2017

Sunanda V Kane

4

1 reference

Europe PubMed Central

25 August 2017

language of work or name

0 references

publication date

6 September 2011

1 reference

Europe PubMed Central

25 August 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

25 August 2017

106

1 reference

Europe PubMed Central

25 August 2017

12

1 reference

Europe PubMed Central

25 August 2017

2070-7; quiz 2078

1 reference

Europe PubMed Central

25 August 2017

https://scigraph.springernature.com/pub.10.1038/ajg.2011.296

0 references

Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

An evidence-based systematic review on medical therapies for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Systematic review: adherence issues in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Measuring therapy adherence in Parkinson's disease: a comparison of methods

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Review article: understanding adherence to medication in ulcerative colitis - innovative thinking and evolving concepts

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.296

21 January 2018

Identifiers

10.1038/AJG.2011.296

1 reference

Europe PubMed Central

25 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

25 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37926915&oldid=2091490744"